China Isotope & Radiation Corporation

HKSE 1763.HK

China Isotope & Radiation Corporation Free Cash Flow for the year ending December 31, 2023: USD -114.46 M

China Isotope & Radiation Corporation Free Cash Flow is USD -114.46 M for the year ending December 31, 2023, a -340.34% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • China Isotope & Radiation Corporation Free Cash Flow for the year ending December 31, 2022 was USD 47.63 M, a -17.45% change year over year.
  • China Isotope & Radiation Corporation Free Cash Flow for the year ending December 31, 2021 was USD 57.69 M, a 419.12% change year over year.
  • China Isotope & Radiation Corporation Free Cash Flow for the year ending December 31, 2020 was USD -18.08 M, a -1,221.80% change year over year.
  • China Isotope & Radiation Corporation Free Cash Flow for the year ending December 31, 2019 was USD 1.61 M, a 106.40% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
HKSE: 1763.HK

China Isotope & Radiation Corporation

CEO Mr. Junqi Zhang
IPO Date July 6, 2018
Location China
Headquarters No. 66 Changwa Middle Street
Employees 3,132
Sector Health Care
Industries
Description

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Independent Clinical Medical and Laboratory Services, and Other Business segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.

Similar companies

1675.HK

Asiainfo Technologies Limited

USD 0.71

1.26%

1773.HK

Tianli International Holdings Limited

USD 0.45

2.01%

1760.HK

Intron Technology Holdings Limited

USD 0.15

2.68%

StockViz Staff

January 15, 2025

Any question? Send us an email